Patents Assigned to FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO)
  • Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
    Patent number: 10968273
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 6, 2021
    Assignees: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTTTUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
  • ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION
    Publication number: 20190119373
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Application
    Filed: May 14, 2018
    Publication date: April 25, 2019
    Applicants: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
  • ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION
    Publication number: 20150139989
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Application
    Filed: January 5, 2015
    Publication date: May 21, 2015
    Applicants: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
  • Antibody recognizing human leukemia inhibitory factor (LIF)
    Patent number: 8926956
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: January 6, 2015
    Assignees: Fundacio Privada Institut d'Investigacio Oncologica Vall d'Hebron (VHIO), Fundacio Privada Institucio Catalana de Recerca I Estudis Avancats (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias